Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 1999

View Archived Issues

Medarex enters HuMAb-Mouse antibody agreement with Amgen

StressGen completes phase I trial of HspE7

NCI to lead phase II trial of Repligen's CTLA4-Ig

Eisai, EORTC initiate phase I testing of novel G1-targeting anticancer sulfonamide

Carbamazepine for the prevention and treatment of alcohol withdrawal syndrome

ER-49890 prolongs graft survival in murine transplantation models

MaxPharma formed to develop L.E.A.P.S. technology

Liposomal foscarnet derivative is a promising treatment for CMV retinitis

DNA-binding agents with a pyrrolylbenzimidazole skeleton claimed by Mitsui Chemicals

Yamanouchi describes new CRF2 receptor antagonists and their use

Selective alpha2B-adrenoceptor ligands developed at Hokuriku

Selective COX-2 inhibitors from UPSA useful for inflammatory and painful conditions

Xoma reports unexpected setback in Neuprex development program

Celltech reports discovery of alpha4 integrin inhibitors

Neurogen's new brain GABA-A receptor ligands presented in patent literature

Paclitaxel/doxorubicin is superior to standard first-line therapy in metastatic breast cancer

New sulfonamide anticoagulants in the Takeda pipeline

HMR presents structures and preliminary data for new coumarin antibiotics at ICAAC

Novel fluoro-2-pyridone antibiotics designed at Abbott; synthesis and SAR discussed at ICAAC

MC-02867 and MC-03260: new water-soluble anti-MRSA cephalosporins

Phase I results of Bavarian Nordic's novel pancreatic cancer therapy reported at ECCO 10

Satraplatin is well tolerated but only marginally effective in cervical cancer

Oxford GlycoSciences presents preliminary clinical trial results for OGT-719 at ECCO 10

SuperGen acquires decitabine from Pharmachemie

Novel HIV-1 protease inhibitor UIC-94-003 exerts potent antiviral activity

Results of small clinical study indicate nefazodone may be effective for diabetic neuropathy

Major medical conference presentation for early data on new amprenavir prodrug

Bay-38-4766: a non-nucleoside inhibitor of HCMV replication in early clinical evaluation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...